Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Mycosis FungoidesNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedT-Cell Prolymphocyte LeukemiaSubgroupCD30+JAK2 rearrangementICD10C82.-C82.7C82.9C83.3C84.0C84.4C84.5C84.6C84.7C84.8C85.2C86.1C86.2C86.5C91.5-C91.6-C94.7-MeSHImmunoblastic LymphadenopathyLeukemia, Prolymphocytic, T-CellLymphoma, FollicularLymphoma, Non-HodgkinLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMycosis FungoidesSequenceSTUDY - levelChemotherapyChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineNo. Substances1234 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPalonosetronPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPalonosetronPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPalonosetronPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPalonosetronPegfilgrastimPotassium chlorideNo. Substances12467Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlConstipationDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityIncrease AminotransferasesInfectionsNeuropathyNeutropeniaPyrexiaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorHeld GHorwitz SMoskowitz AJ Qi FSimon AVan de Wyngaert ZZinzani PLDiseasePeripheres T- oder NK-Zell Lymphom, kutanes T-Zell Lymphom (Stadium IB oder höher), T-PLLperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2Peripheres T-Zell Lymphom, Erstlinie, ECOG 0-2peripheres T-Zell Lymphom, Zweitlinie nach CHOP, ECOG 0-2Peripheres T-Zell Lymphom oder Mykosis fungoides, mindestens 2 Vortherapienrezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3T-Zell Lymphom, Erstlinie, ECOG 0-2OriginCentre Hospitalo-Universitaire (CHU) Grenoble, GOELAMS-LTP95 trialDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), BeijingHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceInstitute of Hematology and Medical Oncology, University of Bologna, Bologna, ItalyInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Memorial Sloan-Kettering Cancer Center, New York, NYMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupMemorial Sloan Kettering Cancer Center, New York, NY, USA, ECHELON-2Protocols in Revision 11 protocols foundProtocols under revision.BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID1799)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma, Variant 1 (PID1773)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204)GDP - Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 25, T-cell Lymphoma (PID2435)Gemcitabine 1200, T-cell Lymphoma (PID1924)Ruxolitinib 20, T-Cell Lymphoma / T-Cell Prolymphocyte Leukemia (PID2478)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972)Study - Level - Nivolumab 3 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID968)Study - Level - Nivolumab 3 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID970)Study - Level - Nivolumab 3, diffuse large B-non-Hodgkin Lymphoma, consolidation (PID971)